Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688016's Return-on-Tangible-Equity is ranked better than 81.37% of 757
companies
in the Medical Devices & Instruments industry
Industry Median: 4.83
vs SHSE:688016: 18.75
Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Shanghai MicroPort Endovascular MedTech (Group) Co Return-on-Tangible-Equity Related Terms
Shanghai MicroPort Endovascular MedTech (Group) Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai MicroPort Endovascular MedTech (Group) Co Return-on-Tangible-Equity Chart
Shanghai MicroPort Endovascular MedTech (Group) Co Annual Data
SHSE:688016 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Shanghai MicroPort Endovascular MedTech (Group) Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai MicroPort Endovascular MedTech (Group) Co Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 21.01% mean?
Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) has a Return-on-Tangible-Equity of 21.01% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shanghai MicroPort Endovascular MedTech (Group) Co and its competitors. This is 17% below median its historical median of 25.21. Over the past decade, Shanghai MicroPort Endovascular MedTech (Group) Co's Return-on-Tangible-Equity has ranged from 16.06 to 77.93. According to the industry distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #141 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 18.6%.
Is Shanghai MicroPort Endovascular MedTech (Group) Co's Return-on-Tangible-Equity too high?
Shanghai MicroPort Endovascular MedTech (Group) Co's current Return-on-Tangible-Equity of 21.01% is 17% below median its 10-year median of 25.21. Over the past 10 years, this metric has ranged from a low of 16.06 to a high of 77.93. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.83. Shanghai MicroPort Endovascular MedTech (Group) Co's value of 21.01% is 335% above this industry median. Based on the distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #141 out of 757 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Shanghai MicroPort Endovascular MedTech (Group) Co has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai MicroPort Endovascular MedTech (Group) Co's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Shanghai MicroPort Endovascular MedTech (Group) Co ranks #141 out of 757 companies for Return-on-Tangible-Equity. This places Shanghai MicroPort Endovascular MedTech (Group) Co in the top 19% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.83. Shanghai MicroPort Endovascular MedTech (Group) Co's value of 21.01% is 335% above this benchmark. Historically, Shanghai MicroPort Endovascular MedTech (Group) Co's own Return-on-Tangible-Equity has ranged from 16.06 to 77.93 over the past decade. While the company's 10-year median is 25.21 vs. the industry median of 4.83, Shanghai MicroPort Endovascular MedTech (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.83, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai MicroPort Endovascular MedTech (Group) Co's current Return-on-Tangible-Equity of 21.01% is 335% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shanghai MicroPort Endovascular MedTech (Group) Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai MicroPort Endovascular MedTech (Group) Co's current Return-on-Tangible-Equity is 21.01%, which is 17% below median its own 10-year median of 25.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai MicroPort Endovascular MedTech (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥117.41, compared to a current price of ¥87.08 — trading 25.8% below its estimated fair value. The current Return-on-Tangible-Equity is 21.01%, which is 17% below median its 10-year median of 25.21 and 335% above the Medical Devices & Instruments industry median of 4.83. Shanghai MicroPort Endovascular MedTech (Group) Co's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016), the current Return-on-Tangible-Equity is 21.01% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai MicroPort Endovascular MedTech (Group) Co (SHSE:688016) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai MicroPort Endovascular MedTech (Group) Co stock appears to be undervalued.
The current stock price of ¥87.08 is trading 25.8% below its estimated GF Value™ of ¥117.41.
GuruFocus considers Shanghai MicroPort Endovascular MedTech (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:688016:
Return-on-Tangible-Equity: 21.01% (17% below median its 10-year median of 25.21)
GF Value™: ¥117.41 vs. price of ¥87.08 (25.8% below fair value)
Industry Position: 335% above the Medical Devices & Instruments median (#141 of 757)
No single metric tells the full story. See the SHSE:688016 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Microport Endovascular Medtech Co Ltd is engaged in the Research, development, production and sales of interventional medical devices for the aorta and peripheral blood vessels.
93GF Score
Get the complete analysis for SHSE:688016
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688016 has been successfully added to your 
